

# Grand Rounds

**Friday, March 1, 9:00am**

## **The New Role(s) of Surgery After Neoadjuvant Systemic Therapy for Cancer**

*featuring*

**Charles M. Balch, MD, FACS, FASCO**  
**Professor of Surgical Oncology; Past-Chair,**  
**Department of Surgical Oncology, The University of**  
**Texas MD Anderson Cancer Center**

**55 Park Street Auditorium | Zoom Access**  
Continental breakfast will be available

**Needs:** Neoadjuvant Systemic Therapy is rapidly changing the sequence of multidisciplinary management of many types of cancer, especially stages II, III and resectable stage IV. Surgery is still valuable for local control, Staging, and prognosis. In some cases no surgery (watch and wait) may be appropriate.

**Objectives:** Understand the difference in treatment planning for systemic chemotherapy and immunotherapy in a Neoadjuvant setting. Understand the importance of surgically documenting the presence of residual tumor burden.



Dr. Charles M. Balch has led a distinguished career as a clinical and academic surgical oncologist for the past 41 years, as a leading authority in both melanoma and breast cancer. He has also made significant contributions to laboratory research in tumor immunology and human T lymphocyte differentiation. He is author of over 760 publications, which have been cited over 24,000 times in the biomedical literature.

Dr. Balch is a Professor and Past-Chair in the Department of Surgical Oncology at MD Anderson. He received his medical degree from Columbia College of Physicians & Surgeons and was founding Director of the Johns Hopkins Clinical Research Network, Johns Hopkins Institute for Clinical and Translational Research at Johns Hopkins.